Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
21178266
DOI
10.3233/cbm-2010-0150
PII: DK294H60687747N6
Knihovny.cz E-resources
- MeSH
- Receptors, Androgen genetics metabolism MeSH
- Butyrates metabolism pharmacology therapeutic use MeSH
- Time Factors MeSH
- Histone Deacetylase 2 metabolism MeSH
- Histone Deacetylases metabolism MeSH
- Immunoprecipitation MeSH
- Histone Deacetylase Inhibitors therapeutic use MeSH
- Nuclear Receptor Co-Repressor 2 genetics metabolism MeSH
- Hydroxamic Acids metabolism pharmacology therapeutic use MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms drug therapy genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Protein Binding genetics MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Receptors, Androgen MeSH
- AR protein, human MeSH Browser
- Butyrates MeSH
- Histone Deacetylase 2 MeSH
- Histone Deacetylases MeSH
- histone deacetylase 3 MeSH Browser
- Histone Deacetylase Inhibitors MeSH
- Nuclear Receptor Co-Repressor 2 MeSH
- Hydroxamic Acids MeSH
- trichostatin A MeSH Browser
Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity. The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. Furthermore, we estimated the reduced presence of HDAC2 and HDAC3 proteins by NaB and TSA treatment in AR-negative DU145 cell line. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor protein.
References provided by Crossref.org